Associations - ER positive

ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials BMC Cancer - 2 weeks
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	exemestane Sensitive: A1 - Approval
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	toremifene Sensitive: A1 - Approval
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline
ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline
ER positive ER positive	Male Breast Cancer Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	neratinib Sensitive: A2 - Guideline
ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	medroxyprogesterone Sensitive: A2 - Guideline
ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	megestrol Sensitive: A2 - Guideline
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	gimeracil/oteracil/tegafur Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	exemestane Sensitive: C1 - Off-label
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant Sensitive: C1 - Off-label
ER positive ER positive	Breast Cancer Breast Cancer	capecitabine Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	SAR439859 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Ovarian Cancer Ovarian Cancer	ribociclib Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	G1T48 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	capecitabine Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	TAK-228 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	H3B-6545 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Endometrial Cancer Endometrial Cancer	ribociclib + letrozole Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Breast Cancer Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	AZD9833 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	everolimus Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	trastuzumab Sensitive: C2 – Inclusion Criteria
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Breast Cancer Breast Cancer	tamoxifen Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	bevacizumab Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	enobosarm Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	AC Sensitive: C3 – Early Trials
ER positive ER positive	Endometrial Cancer Endometrial Cancer	palbociclib + letrozole Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ZN-c5 Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen + TAK-228 Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	lapatinib Resistant: C3 – Early Trials
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + palbociclib Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen + GDC-0032 Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	venetoclax Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ribociclib Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	lapatinib + ado-trastuzumab emtansine Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	zoledronic acid Resistant: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ixazomib Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ponatinib Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ARV-471 Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	MLN8237 Sensitive: C3 – Early Trials
ER positive ER positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ado-trastuzumab emtansine + pertuzumab Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	LY3484356 Sensitive: C3 – Early Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	venetoclax Resistant: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	sunitinib Sensitive: C3 – Early Trials
ER positive ER positive	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	letrozole + zoledronic acid Sensitive: C4 – Case Studies
ER positive ER positive	Gastric Cancer Gastric Cancer	letrozole Sensitive: C4 – Case Studies
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	apalutamide Sensitive: D – Preclinical
ER positive ER positive	Ovarian Cancer Ovarian Cancer	abemaciclib Sensitive: D – Preclinical
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	doxorubicin hydrochloride Resistant: D – Preclinical
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	docetaxel Resistant: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	RGT-419B Sensitive: D – Preclinical
ER positive ER positive	Endometrial Cancer Endometrial Cancer	abemaciclib + letrozole Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	MLN4924 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant + MLN4924 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib + CGM097 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CGM097 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	levo-tetrahydropalmatine Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	MK-2206 + D9 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	SNG-162 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib + CR-1-31-B Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	darolutamide Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	enzalutamide Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	abemaciclib Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib + ZEN-3694 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	abemaciclib + ZEN-3694 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib + APG-2575 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	paclitaxel + eribulin mesylate Sensitive: D – Preclinical
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	XMT-1660 Sensitive: D – Preclinical
ER positive ER positive	Breast Cancer Breast Cancer	everolimus + abemaciclib + alpelisib + LY3484356 Sensitive: D – Preclinical
ER positive ER positive	Breast Cancer Breast Cancer	LY3484356 Sensitive: D – Preclinical
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	Q901 Sensitive: D – Preclinical
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	E7090 Sensitive: D – Preclinical
ER positive ER positive	Breast Cancer Breast Cancer	SCR6106 Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	sorafenib Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	metformin Sensitive: D – Preclinical
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: D – Preclinical